table of content
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Diabetic Neuropathic Pain Drug
1.2 Key Market Segments
1.2.1 Diabetic Neuropathic Pain Drug Segment by Type
1.2.2 Diabetic Neuropathic Pain Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Diabetic Neuropathic Pain Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Diabetic Neuropathic Pain Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Diabetic Neuropathic Pain Drug Market Competitive Landscape
3.1 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2019-2024)
3.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Diabetic Neuropathic Pain Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Diabetic Neuropathic Pain Drug Sales Sites, Area Served, Product Type
3.6 Diabetic Neuropathic Pain Drug Market Competitive Situation and Trends
3.6.1 Diabetic Neuropathic Pain Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Diabetic Neuropathic Pain Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Diabetic Neuropathic Pain Drug Industry Chain Analysis
4.1 Diabetic Neuropathic Pain Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Diabetic Neuropathic Pain Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Diabetic Neuropathic Pain Drug Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2019-2024)
6.3 Global Diabetic Neuropathic Pain Drug Market Size Market Share by Type (2019-2024)
6.4 Global Diabetic Neuropathic Pain Drug Price by Type (2019-2024)
7 Diabetic Neuropathic Pain Drug Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Diabetic Neuropathic Pain Drug Market Sales by Application (2019-2024)
7.3 Global Diabetic Neuropathic Pain Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Diabetic Neuropathic Pain Drug Sales Growth Rate by Application (2019-2024)
8 Diabetic Neuropathic Pain Drug Market Segmentation by Region
8.1 Global Diabetic Neuropathic Pain Drug Sales by Region
8.1.1 Global Diabetic Neuropathic Pain Drug Sales by Region
8.1.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Diabetic Neuropathic Pain Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Diabetic Neuropathic Pain Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Astellas Pharma Inc.
9.1.1 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Basic Information
9.1.2 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Overview
9.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.1.4 Astellas Pharma Inc. Business Overview
9.1.5 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
9.1.6 Astellas Pharma Inc. Recent Developments
9.2 AstraZeneca Plc
9.2.1 AstraZeneca Plc Diabetic Neuropathic Pain Drug Basic Information
9.2.2 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Overview
9.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Market Performance
9.2.4 AstraZeneca Plc Business Overview
9.2.5 AstraZeneca Plc Diabetic Neuropathic Pain Drug SWOT Analysis
9.2.6 AstraZeneca Plc Recent Developments
9.3 BioDelivery Sciences International, Inc.
9.3.1 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.3.2 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug SWOT Analysis
9.3.5 BioDelivery Sciences International, Inc. Business Overview
9.3.6 BioDelivery Sciences International, Inc. Recent Developments
9.4 Boehringer Ingelheim GmbH
9.4.1 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Basic Information
9.4.2 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Overview
9.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Market Performance
9.4.4 Boehringer Ingelheim GmbH Business Overview
9.4.5 Boehringer Ingelheim GmbH Recent Developments
9.5 Daiichi Sankyo Company, Limited
9.5.1 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Basic Information
9.5.2 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Overview
9.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Market Performance
9.5.4 Daiichi Sankyo Company, Limited Business Overview
9.5.5 Daiichi Sankyo Company, Limited Recent Developments
9.6 Dong-A Socio Group
9.6.1 Dong-A Socio Group Diabetic Neuropathic Pain Drug Basic Information
9.6.2 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Overview
9.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Market Performance
9.6.4 Dong-A Socio Group Business Overview
9.6.5 Dong-A Socio Group Recent Developments
9.7 Eli Lilly and Company
9.7.1 Eli Lilly and Company Diabetic Neuropathic Pain Drug Basic Information
9.7.2 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Overview
9.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Market Performance
9.7.4 Eli Lilly and Company Business Overview
9.7.5 Eli Lilly and Company Recent Developments
9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Basic Information
9.8.2 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Overview
9.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Market Performance
9.8.4 Glenmark Pharmaceuticals Ltd. Business Overview
9.8.5 Glenmark Pharmaceuticals Ltd. Recent Developments
9.9 Hydra Biosciences, Inc.
9.9.1 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.9.2 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.9.4 Hydra Biosciences, Inc. Business Overview
9.9.5 Hydra Biosciences, Inc. Recent Developments
9.10 Immune Pharmaceuticals Inc.
9.10.1 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Basic Information
9.10.2 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Overview
9.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.10.4 Immune Pharmaceuticals Inc. Business Overview
9.10.5 Immune Pharmaceuticals Inc. Recent Developments
9.11 Laboratorios Del Dr. Esteve S.A.
9.11.1 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Basic Information
9.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Overview
9.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Market Performance
9.11.4 Laboratorios Del Dr. Esteve S.A. Business Overview
9.11.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
9.12 Lohocla Research Corporation
9.12.1 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Basic Information
9.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Overview
9.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Market Performance
9.12.4 Lohocla Research Corporation Business Overview
9.12.5 Lohocla Research Corporation Recent Developments
9.13 Mertiva AB
9.13.1 Mertiva AB Diabetic Neuropathic Pain Drug Basic Information
9.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Product Overview
9.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Product Market Performance
9.13.4 Mertiva AB Business Overview
9.13.5 Mertiva AB Recent Developments
9.14 Novaremed
9.14.1 Novaremed Diabetic Neuropathic Pain Drug Basic Information
9.14.2 Novaremed Diabetic Neuropathic Pain Drug Product Overview
9.14.3 Novaremed Diabetic Neuropathic Pain Drug Product Market Performance
9.14.4 Novaremed Business Overview
9.14.5 Novaremed Recent Developments
9.15 Pharmaleads
9.15.1 Pharmaleads Diabetic Neuropathic Pain Drug Basic Information
9.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Product Overview
9.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Product Market Performance
9.15.4 Pharmaleads Business Overview
9.15.5 Pharmaleads Recent Developments
9.16 RAPID Pharmaceuticals AG
9.16.1 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Basic Information
9.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Overview
9.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Market Performance
9.16.4 RAPID Pharmaceuticals AG Business Overview
9.16.5 RAPID Pharmaceuticals AG Recent Developments
9.17 Relmada Therapeutics, Inc.
9.17.1 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.17.4 Relmada Therapeutics, Inc. Business Overview
9.17.5 Relmada Therapeutics, Inc. Recent Developments
9.18 Sphaera Pharma Pvt. Ltd.
9.18.1 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Basic Information
9.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Overview
9.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Market Performance
9.18.4 Sphaera Pharma Pvt. Ltd. Business Overview
9.18.5 Sphaera Pharma Pvt. Ltd. Recent Developments
9.19 Theravasc, Inc.
9.19.1 Theravasc, Inc. Diabetic Neuropathic Pain Drug Basic Information
9.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Overview
9.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Market Performance
9.19.4 Theravasc, Inc. Business Overview
9.19.5 Theravasc, Inc. Recent Developments
10 Diabetic Neuropathic Pain Drug Market Forecast by Region
10.1 Global Diabetic Neuropathic Pain Drug Market Size Forecast
10.2 Global Diabetic Neuropathic Pain Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Diabetic Neuropathic Pain Drug Market Size Forecast by Country
10.2.3 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast by Region
10.2.4 South America Diabetic Neuropathic Pain Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Diabetic Neuropathic Pain Drug by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Diabetic Neuropathic Pain Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Diabetic Neuropathic Pain Drug by Type (2025-2030)
11.1.2 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Diabetic Neuropathic Pain Drug by Type (2025-2030)
11.2 Global Diabetic Neuropathic Pain Drug Market Forecast by Application (2025-2030)
11.2.1 Global Diabetic Neuropathic Pain Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Diabetic Neuropathic Pain Drug Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings